Citation only
via OpenAlex
Cerebrovascular disease, amyloid, and neurodegeneration in Alzheimer’s disease progression
Journal of Nuclear Medicine · 2018
Abstract
79 Background: Cerebrovascular disease (CVD) is not currently considered a core pathological feature of Alzheimer’s disease (AD), but concurrent CVD may exacerbate AD progression (Brickman et al, 2015). Objectives: The purpose of this study was first to examine the relationship among amyloid, CVD, and neurodegeneration among individuals with AD, mild cognitive impairment (MCI), and healthy controls, and second, to examine the extent to which amyloid and CVD pathology drive neurodegeneration over time.
Methods: Six hundred eight subjects (222 normal(NL), 291 MCI, 93 AD) from the Alzheimer’s Disease Neuroimaging Initiative underwent longitudinal AV45 PET imaging, as well as T1- and T2-weighted MRI scans to quantify amyloid, white matter hyperintensities (WMHs), and cortical thickness, respectively. AV45 standard uptake value ratio (SUVR) was estimated as the ratio of cortical regions to a composite white matter reference region. White matter hyperintensity volume, an indication of CVD, was derived with T1- and T2-weighted MRI using a Bayesian Markov-Random Field approach with spatial and contextual prior probabilities. Mean cortical thickness in AD-associated regions was measured with the FreeSurfer 5.1 longitudinal processing stream. A series of linear mixed-effects models tested for: 1) differences in AV45 SUVR, WMH volume, and cortical thickness between diagnostic groups 2) the relationship among the three image-derived biomarker measures 3) differences in rates of change over time in biomarkers across diagnostic groups 4) the relationship between longitudinal rate of change in cortical thickness, an indication of neurodegeneration, and baseline amyloid or WMH volume. Covariates included mean-centered age (baseline: 73.4±6.9yrs), APOE-ɛ4 status (359 APOE- ɛ4+), sex (326M), education (16.1±2.1yrs), and intracranial total volume (baseline: 1519.8±159.7cm3). Results: Across diagnostic groups, AV45 SUVR increased (NL MCI,AD), with or without age adjustment (Table1). In a model including all three imaging biomarkers, increased AV45 SUVR and WMH volume were both significantly associated with decreased cortical thickness, but after full covariate adjustment, AV45 SUVR and age, but not WMH volume, were significant (Figure1). AV45 SUVR rate decreased across diagnostic groups (NL>AD), indicating a possible plateau, whereas WMH volume rate increased on the trend level (Table 1). Cortical thinning rate slightly decreased across diagnostic groups (NL
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Lao, P.J. (2018). Cerebrovascular disease, amyloid, and neurodegeneration in Alzheimer’s disease progression. <em>Journal of Nuclear Medicine</em>. https://openalex.org/W2955631928
Vancouver
Lao PJ. Cerebrovascular disease, amyloid, and neurodegeneration in Alzheimer’s disease progression. Journal of Nuclear Medicine. 2018.
BibTeX
@article{patrick2018Cerebr,
title = {Cerebrovascular disease, amyloid, and neurodegeneration in Alzheimer’s disease progression},
author = {Patrick J. Lao},
journal = {Journal of Nuclear Medicine},
year = {2018},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2020
Open access · CC-BY
Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
Alzheimer s & Dementia 2022
Preprint · CC0
Biological Brain Age Prediction Using Machine Learning on Structural Neuroimaging Data: Multi‐Cohort Validation Against Biomarkers of Alzheimer’s Disease and Neurodegeneration
Neurology 2016
Open access · OA
Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia
Annals of Neurology 2017
Preprint · OA
Age, vascular health, and Alzheimer disease biomarkers in an elderly sample
Molecular neurodegeneration 2026
Citation only
Tau extent outperforms tau load as a predictor of neurodegeneration in Alzheimer's disease.
Alzheimer s Research & Therapy 2018
Open access · CC-BY